Good news for the approximately two million Americans with psoriatic arthritis (PsA). Those with active disease now have two new treatment options: the U.S. Food and Drug Administration (FDA) in December approved both ixekizumab (Taltz) and tofacitinib (Xeljanz) for the treatment of PsA.
The U.S. Food and Drug Administration (FDA) has approved the biologic drug abatacept (Orencia) to treat psoriatic arthritis (PsA) in adults. It’s already approved for rheumatoid arthritis (RA) and for one subtype of juvenile idiopathic arthritis (JIA).
Abatacept is a biologic medication that works by targeting T-lymphocytes (T cells), immune cells that are overproduced in people with inflammatory arthritis. The drug, technically called a “selective costimulation modulator,” attaches to the surface of the cells, preventing them from communicating with other cells and producing chemicals that can lead to joint damage and symptoms like pain and swelling. It’s given as a monthly infusion or weekly injection.